The concept of MYC/mTOR dual targeting has been well reviewed by Kumar et al., and the pre-clinical synergistic anti-tumor effect on MYC-driven medulloblastoma cells has been observed [39,40]. This evidence concerns the gene MTOR and medulloblastoma.